Volume 28, Issue 1 (Avicenna Journal of Clinical Medicine-Spring 2021)
Avicenna J Clin Med 2021, 28(1): 5-12 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Fayazi A, Seifodin S, Moradi A. Effects of Pyridoxine on Improving Attention Deficit Hyperactivity Disorder Symptoms among Children under Ritalin Treatment. Avicenna J Clin Med 2021; 28 (1) :5-12
URL: http://sjh.umsha.ac.ir/article-1-2197-en.html
URL: http://sjh.umsha.ac.ir/article-1-2197-en.html
1- Assosiat Professor, Department of Pediatrics, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran , afshin_fay@yahoo.com
2- Pediatrician, Hamadan University of Medical Sciences, Hamadan, Iran
3- Instractor, Department of Community Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2- Pediatrician, Hamadan University of Medical Sciences, Hamadan, Iran
3- Instractor, Department of Community Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (2374 Views)
Background and Objective: Attention Deficit Hyperactivity Disorder (ADHD) is a common neuropsychological disorder among children that might lead to disruption of daily activities. Therefore, this study aimed to determine the effects of pyridoxine on the treatment and reduction of symptoms severity in children with ADHD under Ritalin treatment.
Materials and Methods: This clinical trial included a total of 50 children with ADHD in the age range of 5-12 years who were referred to Emam clinic of Children’s Neurology and Be’sat Hospital, Hamedan, Iran, and were selected using a convenience sampling approach. The participants were divided into two similar treatment groups. One group only received Ritalin as the treatment and the second group received Pyridoxine and Ritalin together. The change in the severity of the symptoms was analyzed using Conners Rating Scale.
Results: The patients in the two treatment groups were identical in terms of age and gender. The mean score of disease severity in both groups reduced up to 23.92 and 32.12 units, respectively, compared to those before intervention (P<0.001). In addition, there was a statistically significant difference between the severity of symptoms before and after intervention in both groups following the intervention (the mean scores of the severity of symptoms were obtained at 65.09 and 54.00, respectively) in children with ADHD (P=0.006).
Conclusion: The addition of Pyridoxine tablets to the treatment diet of children in the age range of 5-12 years suffering from combined symptoms of ADHD led to further reduction of symptoms and an increase in the effectiveness of the treatment.
Materials and Methods: This clinical trial included a total of 50 children with ADHD in the age range of 5-12 years who were referred to Emam clinic of Children’s Neurology and Be’sat Hospital, Hamedan, Iran, and were selected using a convenience sampling approach. The participants were divided into two similar treatment groups. One group only received Ritalin as the treatment and the second group received Pyridoxine and Ritalin together. The change in the severity of the symptoms was analyzed using Conners Rating Scale.
Results: The patients in the two treatment groups were identical in terms of age and gender. The mean score of disease severity in both groups reduced up to 23.92 and 32.12 units, respectively, compared to those before intervention (P<0.001). In addition, there was a statistically significant difference between the severity of symptoms before and after intervention in both groups following the intervention (the mean scores of the severity of symptoms were obtained at 65.09 and 54.00, respectively) in children with ADHD (P=0.006).
Conclusion: The addition of Pyridoxine tablets to the treatment diet of children in the age range of 5-12 years suffering from combined symptoms of ADHD led to further reduction of symptoms and an increase in the effectiveness of the treatment.
Type of Study: Original |
Subject:
Pediatrics (all specialties)
Extended Abstract [HTML 26 KB] (137 Download)
References
1. Travis F, Grosswald S, Stixrud W. ADHD, brain functioning, and transcendental meditation practice. Mind Brain J Psychiatr. 2011;2(1):73-81.
2. Sadock BJ, Sadock VA. Kaplan and Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. Philadelphia: Lippincott Williams & Wilkins; 2011.
3. Grizenko N, Shayan YR, Polotskaia A, Ter-Stepanian M, Joober R. Relation of maternal stress during pregnancy to symptom severity and response to treatment in children with ADHD. J Psychiatry Neurosci. 2008;33(1):10-6. PMID: 18197267
4. Linnet KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, Rodriguez A, et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry. 2003;160(6):1028-40. PMID: 12777257 DOI: 10.1176/appi.ajp.160.6.1028
5. Amiri S, Fakhari A, Golmirzaei J, Mohammadpoorasl A, Abdi S. Tourette's syndrome, chronic tics, and comorbid attention deficit/hyperactivity disorder in elementary students. Arch Iran Med. 2012;15(2):76-8. PMID: 22292574
6. Singh P, Patil Y, Rale V. Biosurfactant production: emerging trends and promising strategies. J Appl Microbiol. 2019;126(1):2-13. PMID: 30066414 DOI: 10.1111/jam.14057
7. Ohadi M, Forootanfar H, Rahimi HR, Jafari E, Shakibaie M, Eslaminejad T, et al. Antioxidant potential and wound healing activity of biosurfactant produced by Acinetobacter junii B6. Curr Pharm Biotechnol. 2017;18(11):900-8. PMID: 29173159 DOI: 10.2174/1389201018666171122121350
8. Wang LJ, Yu YH, Fu ML, Yeh WT, Hsu JL, Yang YH, et al. Attention deficit–hyperactivity disorder is associated with allergic symptoms and low levels of hemoglobin and serotonin. Sci Rep. 2018;8(1):10229. PMID: 29980754 DOI: 10.1038/s41598-018-28702-5
9. Bhagavan HN, Coleman M, Coursin DB. The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics. 1975;55(3):437-41. PMID: 1143984
10. Coleman M, Steinberg G, Tippett J, Bhagavan H, Coursin D, Gross M, et al. A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: a double-blind crossover comparison with methylphenidate. Biol Psychiatry. 1979;14(5):741-51. PMID: 497303
11. Brenner A, Wapnir RA. A pyridoxine-dependent behavioral disorder unmasked by isoniazid. Am J Dis Child. 1978;132(8):773-6. PMID: 150790 DOI: 10.1001/archpedi.1978.02120330045011
12. Dolina S, Margalit D, Malitsky S, Rabinkov A. Attention-deficit hyperactivity disorder (ADHD) as a pyridoxine-dependent condition: Urinary diagnostic biomarkers. Med Hypotheses. 2014;82(1):111-6. PMID: 24321736 DOI: 10.1016/j.mehy.2013.11.018
13. Rucklidge JJ, Eggleston MJF, Darling KA, Stevens AJ, Kennedy MA, Frampton CM. Can we predict treatment response in children with ADHD to a vitamin-mineral supplement? An investigation into pre-treatment nutrient serum levels, MTHFR status, clinical correlates and demographic variables. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:181-92. PMID: 30217770 DOI: 10.1016/j.pnpbp.2018.09.007
14. Landaas ET, Aarsland TI, Ulvik A, Halmøy A, Ueland PM, Haavik J. Vitamin levels in adults with ADHD. BJP sych Open. 2016;2(6):377-84. PMID: 27990293 DOI: 10.1192/bjpo.bp.116.003491
15. Mousain-Bosc M, Roche M, Rapin J, Bali JP. Magnesium VitB6 intake reduces central nervous system hyperex-citability in children. J Am Coll Nutr. 2004;23(5):545S-8S. PMID: 15466962 DOI: 10.1080/07315724.2004.10719400
16. Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali J. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. Magnes Res. 2006;19(1):53-62. PMID: 16846101
17. Zarei Z. Preparation of polyvinyl alcohol / amino acid nanofiber wound dressings containing antibiotics. [Master Thesis]. Yazd: Azad University of Polymer Engineering; 2016. [In Persian]
18. Alizadeh H. A theoretical explanation on attention deficit/hyperactivity disorder: behavioral inhibition model and nature of self-control. J Excep Child. 2005;17(3):323-48. [In Persian]
19. Nogovitsina O, Levitina E. Effect of MAGNE-B6 on the clinical and biochemical manifestations of the syndrome of attention deficit and hyperactivity in children. Eksp Klin Farmakol. 2006;69(1):74-7. PMID: 16579066
20. Amen DG. Magnificent mind at any age: natural ways to unleash your brain's maximum potential. New York: Harmony; 2009.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences
Published by UMSHA Press
Journal Tel: +988138380924
Publisher Tel:+988138380548
Website: http://sjh.umsha.ac.ir
Email: s_ journal[at]umsha.ac.ir
